Developing Novel Therapies to Enhance Patients' Lives
Tolera Therapeutics is developing novel therapies and technologies, to offer patients and their doctors, targeted and safer solutions, for immune modulation and related medical needs.
Developing more targeted and safer immune response therapies.
Tolera Therapeutics Announces closing of Series B-3 funding
Tolera Therapeutics Announces Appointment of Linda C. Hogan, VP of Business Development
Tolera Therapeutics granted Orphan Drug Designation for treatment of Type 1 diabetes mellitus
Tolera granted Orphan Drug Designation for organ transplant rejection drug
See Related Articles...
© 2011 Tolera Therapeutics, Inc. 350 E. Michigan Avenue, Suite 205, Kalamazoo, MI 49007
Terms & Conditions